Longitudinal Follow-up After C1 Implant Stabilization Values
|ClinicalTrials.gov Identifier: NCT01746160|
Recruitment Status : Unknown
Verified September 2013 by Lior Shapira, Hadassah Medical Organization.
Recruitment status was: Recruiting
First Posted : December 10, 2012
Last Update Posted : September 10, 2013
The aim of the study is to describe the changes found in C1 dental implants through their early healing period.
Patients requiring a standard installation of one or two implants in the maxilla, without any need for bone augmentation, will be frequently followed for 90 days. In every meeting the implants' ISQ values (values denoting the implant stability as being measured by a dedicated, commercially available, appliance called 'Osstell').
The implants' measured ISQ values will be used to describe the changes that may be found in the implants' stability through their healing period.
At the end of the study the patients will be referred to their treating doctor for the completion of implants' restoration (i.e. crown).
|Condition or disease||Intervention/treatment||Phase|
|Jaw, Edentulous, Partially||Drug: C1 Implant||Not Applicable|
10 Patients requiring standard implant installation in their maxilla will be recruited to the study.
- Men and women over the age of 18.
- The patient will be willing, and will be available to attend all the follow-up meetings.
- The patient will accept and sign an informed consent form before the beginning of the study.
- Pregnant women or women who are breast feeding.
- Patient suffering of untreated periodontal disease.
- Patient who smoke more than 10 cigarettes per day.
- Alcohol abuse.
- Patient suffering of either uncontrolled Diabetes, Osteoporosis, rheumatic arthritis, neoplastic or pre-cancerous condition, or any other condition limiting standard implant installation procedure.
- Patient who need some bone augmentation prior.
- Immediate implant placement or restorations.
Course of study:
Every patient found eligible to the study will need to go through a CT scan of the implantation site (as required).
Before the operation 2 gr of AMOXICILLIN (or 600mg of CLYNDAMYCIN - in case of allergy) will be administered. The implants will be installed in a standard approach under local anesthesia, as customary being done. The implants' installation torque will be recorded.
At the end of the operation the patients will be instructed to rinse their mouth with Chlorhexidine solution for one week.
Eventually the implants will be restored and loaded after the common 3 months healing period.
The patients will be monitored through a period of 3 months. The patients will be instructed to return to a follow-up examination 2, 4, 7, 14, 21, 28, 45, 60 and 90 days after the operation. On each meeting the implants' ISQ values will be measured using an 'Osstell' appliance.
An x-ray intra-oral radiogram will be taken right after the end of the operation and at the end of the follow-up (i.e day 90).
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Short-term Longitudinal Follow-up After C1 Implant Stability Values.|
|Study Start Date :||December 2012|
|Estimated Primary Completion Date :||December 2013|
|Estimated Study Completion Date :||December 2013|
Experimental: C1 Implant
Patient having C1 implant installed.
Drug: C1 Implant
Patients treated with dental implants.
- Change from baseline in implant ISQ value. [ Time Frame: 90 days (at end of the follow-up). ]The change in implants' stability values that were measured by an 'Osstell' appliance at the end of the study as compared to their baseline value.
- Implant Marginal Bone Loss (MBL). [ Time Frame: 90 days (At the end of the follow-up). ]The amount of the marginal bone loss (MBL) as measured by comparing two intra-oral radiogram taken right after the operation and at the end of the follow-up period.
- Implant survival rate. [ Time Frame: 90 days (At the end of the follow-up). ]The rate of the implants found to be integrated at the end of the study (100% is anticipated).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01746160
|Contact: Lior Shapira, Prof.||+email@example.com|
|Contact: Moshik Tandlich, D.M.Dfirstname.lastname@example.org|
|Hadassah Medical Organization||Recruiting|
|Contact: Hadas Lemberg, PhD 00 972 2 6777572 email@example.com|
|Principal Investigator: Lior Shapira, Prof.|
|Sub-Investigator: Moshik Tandlich, D.M.D|
|Principal Investigator:||Hadas Lemberg, PhD||IRB coorinator|